Kyowa Hakko Kirin Co., Limited

Osaka University

Gunma University

Nard Institute, Ltd.

Knc Laboratories Co., Ltd.

J-pharma Co., Ltd.

Human Cell Systems, Inc.

Endou, Hitoshi

Yoshikatsu Kanai

Tetsuya Yoshino

Shiro Kataoka

Tomoyuki Tahara

Kazumasa Hasegawa

Hitoshi Endou

Shushi Nagamori

Masahiro Neya

Atsushi Enomoto

Kazuko Kaneda

Jun Hatazawa

Yoshifumi Shirakami

Atsushi Shinohara

Koichi Fukase

Hidekazu Nakao

Tokutaro Ogata

Naohiro Matsushita

Yoshihiko Kitaura

Kyoichi Kaira

Goshi Ishihara

Kunio Saito

Kenji Tsujihara

Kazuya Kabayama

Zijian Zhang

Atsushi Shimoyama

Yoshiyuki Manabe

Methods are provided for predicting a response to an anti-PD-1 antibody or anti-PD-L1 antibody therapy based on a new biomarker and for evaluating a malignancy of cancer. The method for predicting a response of a subject to an anti-PD-1 antibody or anti-PD-L1 antibody therapy includes measuring an expression level of LAT1 in a sample collected from a cancer tissue of the subject; and predicting a response of the subject to the anti-PD-1 antibody or anti-PD-L1 antibody therapy based on the expression level of LAT1. The method for evaluating a malignancy of cancer in a subject includes staining a sample collected from a cancer tissue of the subject with an anti-LAT1 antibody and an anti-PD-L1 antibody; and evaluating a malignancy of the cancer in the subject based on a presence or absence of a LAT1-positive and PD-L1-positive site.

Method for predicting efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy, method for evaluating cancer grade, and method for enhancing efficacy of anti-PD-1 antibody or anti-PD-L1 antibody therapy

A compound having a structure represented by the general formula (I): (wherein n is 0 or 1;Rrepresents a hydrogen atom (only if n=0), a halogen atom, a C1-C6 alkyl group, a C1-C6 haloalkyl group, an optionally substituted amino group, an optionally substituted phenyl group, a C1-C6 alkylthio group, a C1-C6 alkoxy group, a C1-C6 haloalkoxy group or a C7-C12 aralkyloxy group;Rrepresents &#x2014;(CH)&#x2014;[O(CH)]&#x2014;X (wherein X is a halogen atom, p is an integer of 1 to 6, q is an integer of 1 to 4, and r is an integer of 0 to 4);Rrepresents a hydrogen atom, a C1-C6 alkyl group, a C7-C16 aralkyl group or a C6-C14 aryl group; andRrepresents a hydrogen atom or a C1-C6 alkyl group), or a pharmaceutically acceptable salt thereof excels FAMT in terms of the tendency to accumulate intensively in cancer, the affinity for LAT1 and the selectivity for cancer, and can be labeled using an automated synthesizer in clinical settings, and therefore is useful as a highly versatile PET imaging agent.

Aromatic amino acid derivative and positron emission topography (PET) probe using the same

The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.

Phenoxyalkylamine compound

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

Anti-CD98 antibody processes

Anti-CD98 antibody

Growing community of inventors

Suita, Japan

Yoshikatsu Kanai